

Defining Success on Access & Metrics to Track Progress

July 27, 2010

PDP Access Meeting

How PDPs Define Success

- ***MVI***
 - success linked to the facilitation of country decision making, using malaria vaccine decision making framework
- ***TB Alliance***
 - success linked country adoption: “programs considered likely to adopt TB Alliance developed regimen within 3 years”
- ***MMV***
 - success linked to whole portfolio: creating informed acceptance platforms and facilitating support of all new antimalarials on the market (ex supporting innovative programs such as AMFm)

Usefulness of Defining Success

- Help with planning and priorities
- Orients the strategy around overarching goal
- Narrow scope of issues = useful focus
- Linked to country adoption = only products wanted by countries
- Broad scope (all related products) = wide disease impact
- Others?

How to Measure Access Success?

- **What metrics will be used to measure these?**
- **Who will measure, how and who will pay?**
- **What are the other 10 or 11 PDPs using to define success?**
- **Ideas for adoption success metrics**
 - volume of product sold/# of users adopting
 - # of countries with product registered
 - time from SRA registration to WHO PQ
 - time to purchase by countries
 - time to first use
 - Etc.

What about pre-launch access metrics?

- **Interim success indicators for our day to day work, not just post-licensure adoption**
- **Demonstrate our contribution internally & externally**
- **Possible metrics**
 - # of countries visited
 - # of program managers met with to discuss product
 - # of “exposures” of decision makers to product info
 - # of studies about countries’ needs and product preferences
 - # of countries saying they will adopt
 - changes made to TPP
 - portfolio or clinical trials as a result of access discussions
 - etc.